Monday, November 9, 1998
The ideal drug would exhibit pure action at a single site.
Such pinpoint precision would work as if a single gene were switched off. Rosetta
Inpharmatics is pursuing technology aimed at helping drug designers determine
if their compounds have such precision.
The approach uses cDNAs from yeast knock-out mutants and from
drug-treated yeasts to make comparisons of gene expression. Writing in Nature
Medicine, the company showed that the degree of overlap of patterns of gene
expression may predict side effects or suggest alternate therapeutic targets.